Overview
Biopharmaceutical firm's Q4 revenue miss analyst expectations
Adjusted EPS for Q4 missed analyst expectations
BAQSIMI sales increased due to higher unit volumes from U.S. marketing efforts
Outlook
Amphastar to scale U.S. manufacturing for growth phase
Result Drivers
BAQSIMI SALES - Increased due to higher unit volumes from U.S. marketing efforts
GLUCAGON SALES DECLINE - Decreased due to lower pricing and unit volumes amid competition
NEW PRODUCT LAUNCHES - Iron sucrose and other products contributed to revenue
Company press release: ID:nACSY4nRqa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $183.11 mln | $190.48 mln (6 Analysts) |
Q4 Adjusted EPS | Miss | $0.73 | $0.92 (7 Analysts) |
Q4 EPS | $0.51 | ||
Q4 Adjusted Net Income | Miss | $34.16 mln | $43.60 mln (6 Analysts) |
Q4 Net Income | $24.43 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Amphastar Pharmaceuticals Inc is $30.00, about 7.3% above its February 25 closing price of $27.97
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 7 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments